birth defects | GenomeWeb

birth defects

The company's new clinical laboratory will provide interim and backup services for its customers.

The UK NIPT firm said that is creating a provision of £500,000 to cover expected expenses related to litigation involving Illumina.

The four-year project aims to sequence about 800 kids and their parents to get a clearer idea of the genetic underpinnings of birth defects with unknown causes. 

The Suzhou, China-based laboratory will focus on neonatal testing and infectious diseases, with the potential to expand into cancer testing. 

NEW YORK (GenomeWeb News) – Researchers from Stephen Quake's laboratory at Stanford University have a published a method in Nature describing a way to noninvasively sequence a fetal genome and identify clinically relevant alleles without prior knowledge of paternal genetic data.

A new, $4 million per-year grant program will fund basic and translational studies of the genetic and molecular basis of congenital birth defects.

Quest, whose ClariSure test is based on a bacterial artificial chromosome array, is also considering adopting oligonucleotide array-based platforms sold by companies such as Affymetrix, Agilent Technologies, Illumina, and others.

BioArray Briefs

Premium

Quest Diagnostics, Centre for Proteomic and Genomic Research, SimuGen, Arrayit, Phalanx, Rosetta Biosoftware, Exiqon, Norgen Biotek, TcLand Expression, Genedata, GeneGo, Entelos, Integrated DNA Technologies, VH Bio, SciGene, Inter Medico

Pages

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.